

Our vision is to revolutionize respiratory health by harnessing what is made in our lungs.
We are dedicated to pioneering innovative solutions that significantly reduce the severity of lung injury, including that caused by pneumonia and complications from transplantation. Through our commitment to cutting-edge research, collaboration, training and mentoring, we strive to improve the quality of life for patients worldwide, ensuring that every breath counts.
News
Hrish Kulkarni was elected to the American Society of Clinical Investigation (ASCI). Read about the ASCI, a list of the members elected in 2025, and the announcement.
The Kulkarni Lab moved to the University of California Los Angeles (UCLA) on October 1, 2024 with a focus on strengthening the program in lung injury and women’s lung health. We look forward to continuing our collaborations and developing new ones!
Lorena Garnica and Angel Lu both presented their work at the 2024 Joint AAP/ASCI/APSA meeting at Chicago in April 2024. Both are applying for medical school in the coming year, and we wish them all the best!
Publications
Moore BB, Ballinger MN, Bauer NN, Blackwell TS, Borok Z, Budinger GRS, Camoretti-Mercado B, Erzurum SC, Himes BE, Keshamouni VG, Kulkarni HS, Mallampalli RK, Mariani TJ, Martinez FJ, McCombs JE, Newcomb DC, Johnston RA, O’Reilly MA, Prakash YS, Ridge KM, Sime PJ, Sperling AI, Violette S, Wilkes DS, Königshoff M. Building Career Paths for Ph.D., Basic and Translational Scientists in Clinical Departments in the United States: An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2023 Aug;20(8):1077-1087. doi: 10.1513/AnnalsATS.202304-305ST. PMID: 37526479; PMCID: PMC10405615.
Annane D, Pittock SJ, Kulkarni HS, Pickering BW, Khoshnevis MR, Siegel JL, Powell CA, Castro P, Fujii T, Dunn D, Smith K, Mitter S, Kazani S, Kulasekararaj A. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2023 Mar 20:S2213-2600(23)00082-6.
Sahu SK, Ozanturk AN, Kulkarni DH, Ma L, Barve RA, Dannull L, Lu A, Starick M, McPhatter J, Garnica L, Sanfillipo-Burchman M, Kunen J, Wu X, Gelman AE, Brody SL, Atkinson JP, Kulkarni HS. Lung epithelial cell-derived C3 protects against pneumonia-induced lung injury. Sci Immunol. 2023 Feb 3;8(80):eabp9547.
Kulkarni HS, Lee JS, Bastarache JA, Kuebler WM, Downey GP, Albaiceta GM, Altemeier WA, Artigas A, Bates JHT, Calfee CS, Dela Cruz CS, Dickson RP, Englert JA, Everitt JI, Fessler MB, Gelman AE, Gowdy KM, Groshong SD, Herold S, Homer RJ, Horowitz JC, Hsia CCW, Kurahashi K, Laubach VE, Looney MR, Lucas R, Mangalmurti NS, Manicone AM, Martin TR, Matalon S, Matthay MA, McAuley DF, McGrath-Morrow SA, Mizgerd JP, Montgomery SA, Moore BB, Noël A, Perlman CE, Reilly JP, Schmidt EP, Skerrett SJ, Suber TL, Summers C, Suratt BT, Takata M, Tuder R, Uhlig S, Witzenrath M, Zemans RL, Matute-Bello G. Update on the Features and Measurements of Experimental Acute Lung Injury in Animals: An Official American Thoracic Society Workshop Report. Am J Respir Cell Mol Biol. 2022 Feb;66(2):e1-e14.